A letter from Paul Giusti
Dear Friends,
Welcome to the latest edition of the MMRF Accelerator. It’s an exciting time for
the MMRF, as we accelerate our search for a cure for each and every multiple
myeloma patient.
As you will see in this issue, our research model continues to generate
incredible momentum. In our Clinical Trial Highlights (page 9), we spotlight
several new trials – including novel and molecularly targeted therapies and
immunotherapies – that are cause for optimism for patients at all stages of
the disease. The MMRF CoMMpass Study SM Update (page 6), highlights the
insights gleaned from our landmark $40 million effort – creating the largest
genomic dataset in all cancers.
You will also learn about two more new MMRF programs to speed
multiple myeloma research. The first is a $15 million investment in the
field of immunotherapy, a treatment approach that harnesses the power
of each patient’s immune system, to fight and kill cancer cells. The MMRF
Immunotherapy Initiative (page 4) invests in an Immunotherapy Network of
Excellence – a collaborative effort to utilize immune approaches to treating
multiple myeloma and use that data to drive new treatments in the clinic.
The second, the MMRF Prevention Project (page 10), is focused on detecting
multiple myeloma in its earliest, most treatable stages and, ultimately, stopping
the disease before it progresses.
These exciting, innovative advances are possible because of the commitment
and collaborative spirit of our many partners – scientists, researchers,
pharmaceutical companies and, most importantly, individuals who support our
research. I look forward to continuing to share our progress with you in the
months to come.
Thank you for your generous and sustained support of our critical mission.
Sincerely,
Paul Giusti
President and Chief Executive Officer
Multiple Myeloma Research Foundation